 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
15 November 1997 | Volume 127 Issue 10 | Pages 904-909
The risk for viral transmission by transfusion has been reduced dramatically through improved techniques for selecting and testing blood donors.Initiatives to further improve the safety of the blood supply, including more stringent donor qualifications, additional testing for infectious disease markers, viral inactivation processes, and refinement of transfusion decisions, are possible. However, because the risk for viral transmission by allogeneic transfusion is already low, additional measures will have limited yield and poor cost-effectiveness. Furthermore, unexpected side effects of some of these "improvements" may reduce the safety of the blood supply by introducing new risks. Cost-effectiveness analyses of blood safety initiatives have highlighted such successes as the introduction of virus-specific assays for screening donated blood and have identified other interventions that have poor cost-effectiveness estimates. They have also quantitated the threshold level at which the risks of an intervention outweigh its benefits. These analyses have had little effect on decisions about blood safety, possibly because of overwhelming fear of AIDS and difficulties in applying cost-effectiveness estimates to a politically and emotionally charged issue. Future interventions for improving blood supply safety must be evaluated thoroughly and chosen carefully so that the intended goals are met. Communication with the public should be undertaken so that the public understands that some of the desired measures may result in inefficient allocation of health care resources.
Author and Article Information
From Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire; Veterans Affairs Medical Center, White River Junction, Vermont; and University of California, San Francisco, California.
PERSPECTIVE
Safety of the Blood Supply in the United States: Opportunities and Controversies
Grant Support: In part by National Heart, Lung, and Blood Institute contract NO1-HB-47114 (Retrovirus Epidemiology Donor Study) (Dr. Busch).
Requests for Reprints: James P. AuBuchon, MD, Department of Pathology, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756.
Current Author Addresses: Dr. AuBuchon: Department of Pathology and Medicine, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756.
This article has been cited by other articles:
|
|
 |
|
  R. S. Weber, N. Jabbour, and R. C. G. Martin II Anemia and Transfusions in Patients Undergoing Surgery for Cancer Ann. Surg. Oncol., January 1, 2008; 15(1): 34 - 45. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The Society of Thoracic Surgeons Blood Conservatio, V. A. Ferraris, S. P. Ferraris, S. P. Saha, E. A. Hessel II, C. K. Haan, B. D. Royston, C. R. Bridges, R. S.D. Higgins, G. Despotis, et al. Perioperative Blood Transfusion and Blood Conservation in Cardiac Surgery: The Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists Clinical Practice Guideline Ann. Thorac. Surg., May 1, 2007; 83(5_Supplement): S27 - S86. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. McCullough, D. H. Vesole, R. J. Benjamin, S. J. Slichter, A. Pineda, E. Snyder, E. A. Stadtmauer, I. Lopez-Plaza, S. Coutre, R. G. Strauss, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial Blood, September 1, 2004; 104(5): 1534 - 1541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. L. Corwin and J. P. AuBuchon Is Leukoreduction of Blood Components for Everyone? JAMA, April 16, 2003; 289(15): 1993 - 1995. [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Hillyer, C. D. Josephson, M. A. Blajchman, J. G. Vostal, J. S. Epstein, and J. L. Goodman Bacterial Contamination of Blood Components: Risks, Strategies, and Regulation: Joint ASH and AABB Educational Session in Transfusion Medicine Hematology, January 1, 2003; 2003(1): 575 - 589. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. D. Weinberg, J. Hounshell, L. A. Sherman, J. Godwin, S. Ali, C. Tomori, and C. L. Bennett Legal, Financial, and Public Health Consequences of HIV Contamination of Blood and Blood Products in the 1980s and 1990s Ann Intern Med, February 19, 2002; 136(4): 312 - 319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Collier, L. A. Kalish, M. P. Busch, T. Gernsheimer, S. F. Assmann, T. A. Lane, D. M. Asmuth, M. M. Lederman, E. L. Murphy, P. Kumar, et al. Leukocyte-Reduced Red Blood Cell Transfusions in Patients With Anemia and Human Immunodeficiency Virus Infection: The Viral Activation Transfusion Study: A Randomized Controlled Trial JAMA, March 28, 2001; 285(12): 1592 - 1601. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. G. Feagan, C. J. Wong, A. Kirkley, D.W.C. Johnston, F. C. Smith, P. Whitsitt, S. L. Wheeler, and C. Y. Lau Erythropoietin with Iron Supplementation To Prevent Allogeneic Blood Transfusion in Total Hip Joint Arthroplasty: A Randomized, Controlled Trial Ann Intern Med, December 5, 2000; 133(11): 845 - 854. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. HATZIDAKIS, M. R. MENDLICK, T. McKILLIP, R. L. REDDY, and K. L. GARVIN Preoperative Autologous Donation for Total Joint Arthroplasty. An Analysis of Risk Factors for Allogenic Transfusion J. Bone Joint Surg. Am., January 1, 2000; 82(1): 89 - 100. [Abstract] [Full Text]
|
|
|
|
|
|
S. I. Strasser and G. B. McDonald Hepatitis Viruses and Hematopoietic Cell Transplantation: A Guide to Patient and Donor Management Blood, February 15, 1999; 93(4): 1127 - 1136. [Full Text] [PDF]
|
|
|
|
 |
|
 L. T. Goodnough, M. E. Brecher, M. H. Kanter, and J. P. AuBuchon Transfusion Medicine -- Blood Transfusion- First of Two Parts N. Engl. J. Med., February 11, 1999; 340(6): 438 - 447. [Full Text] [PDF]
|
|
Article
